Literature DB >> 33748517

Bringing Induced Pluripotent Stem Cell Technology to the Bedside.

Peter Karagiannis1, Ayaka Nakauchi1, Shinya Yamanaka1.   

Abstract

Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state. From a scientific perspective, their discovery has provided a molecular roadmap for turning on and off cell identities, effectively allowing any cell type to have its identity changed into any other cell type. They also act as a human model for understanding the development of every cell and organ in the body. In addition, because they can be prepared from patients, iPSCs offer a unique human model for studying disease development, including many diseases that are generally diagnosed at a late stage of their development. These models have provided new insights on the pathogenesis and new targets to prevent or reverse the disease development process. Indeed, clinical studies on compounds based on drug screening hits in human iPSC disease models have begun. Because of their proliferation and differentiation capacity, iPSCs can also be used to prepare cells for transplantations, and related clinical studies using iPSC-based cell therapies are ongoing. The combination of iPSCs with other technologies or therapeutic strategies is expected to expand their medical benefits. In this review, we consider medical accomplishments based on iPSC research and future ones that can be anticipated.
Copyright © Japan Medical Association.

Entities:  

Keywords:  cell reprogramming; drug discovery; induced pluripotent stem cells; regenerative medicine

Year:  2018        PMID: 33748517      PMCID: PMC7969850          DOI: 10.31662/jmaj.2018-0005

Source DB:  PubMed          Journal:  JMA J        ISSN: 2433-328X


  64 in total

1.  High-Content Screening in hPSC-Neural Progenitors Identifies Drug Candidates that Inhibit Zika Virus Infection in Fetal-like Organoids and Adult Brain.

Authors:  Ting Zhou; Lei Tan; Gustav Y Cederquist; Yujie Fan; Brigham J Hartley; Suranjit Mukherjee; Mark Tomishima; Kristen J Brennand; Qisheng Zhang; Robert E Schwartz; Todd Evans; Lorenz Studer; Shuibing Chen
Journal:  Cell Stem Cell       Date:  2017-07-20       Impact factor: 24.633

2.  The New Federalism: State Policies Regarding Embryonic Stem Cell Research.

Authors:  Nefi D Acosta; Sidney H Golub
Journal:  J Law Med Ethics       Date:  2016-09       Impact factor: 1.718

Review 3.  Cellular reprogramming technology for dissecting cancer epigenome in vivo.

Authors:  Kenji Ito; Yasuhiro Yamada
Journal:  Epigenomics       Date:  2017-06-27       Impact factor: 4.778

4.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

5.  Cellular context-dependent consequences of Apc mutations on gene regulation and cellular behavior.

Authors:  Kyoichi Hashimoto; Yosuke Yamada; Katsunori Semi; Masaki Yagi; Akito Tanaka; Fumiaki Itakura; Hitomi Aoki; Takahiro Kunisada; Knut Woltjen; Hironori Haga; Yoshiharu Sakai; Takuya Yamamoto; Yasuhiro Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-05       Impact factor: 11.205

Review 6.  Induced pluripotent stem cell technology and aquatic animal species.

Authors:  Alexis M Temkin; Demetri D Spyropoulos
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2014-02-15       Impact factor: 3.228

7.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

Review 8.  Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.

Authors:  Michael D Jain; Marco L Davila
Journal:  Stem Cells       Date:  2017-10-25       Impact factor: 6.277

Review 9.  Reprogramming antitumor immunity.

Authors:  Joseph G Crompton; David Clever; Raul Vizcardo; Mahendra Rao; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2014-03-21       Impact factor: 16.687

Review 10.  Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells.

Authors:  Beatrice Xuan Ho; Nicole Min Qian Pek; Boon-Seng Soh
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

View more
  1 in total

Review 1.  Translational potential of hiPSCs in predictive modeling of heart development and disease.

Authors:  Corrin Mansfield; Ming-Tao Zhao; Madhumita Basu
Journal:  Birth Defects Res       Date:  2022-03-09       Impact factor: 2.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.